SALT LAKE CITY, UTAH—Through its Federal Drug Administration (FDA) certification process, FUZE Technology has increased the standard for environmental impact testing and antimicrobial efficacy in the textile industry.
All businesses involved in the textile sector, including distributors, manufacturers, and brands, are generally making every effort to innovate in ways that will improve products and minimize our immediate and long-term environmental effect. Product testing, particularly the widely recognized testing of antimicrobial products, is a crucial indicator of the success of efforts to improve products and the environmental impact of a firm and its products. Many employ “check-the-box” methods, such as industry exams and certifications, to demonstrate that they are making an effort to fulfill a minimum degree of excellence. FUZE, a leading supplier of cutting-edge antimicrobial products with over 15 years of experience in the industry, thinks there’s a better way
According to Andrew Peterson, chief technology officer of FUZE Technology, “The European Union (EU) has voiced its desire to raise anti-microbial testing standards to a level that far exceeds today’s testing, to encompass testing that identifies a product’s efficacy AND its effect on human interaction.”
“Actions for the entire lifecycle of textiles products, while supporting the ecosystem in the green and digital transitions” are what the EU’s policy suggests, according to the article Questions and Answers on EU policy for Sustainable and Circular Textiles European Commission. The EU intends to impose more stringent regulations on greenwashing, including stronger consumer protection guidelines and clear connections to the forthcoming Green Claims Initiative.
“FUZE’s technology produces goods that are utilized as therapeutics and in medical devices. Food and Drug Administration (FDA) testing and methodology for FUZE are currently in progress due to its significance for human heath, according to Peterson. He went on, “FUZE passed the FDA’s pre-investigational new drug application in March 2024, which is a process that directs approvals and is used for early-stage trial strategies.”
Peterson claims that FUZE’s FDA testing far beyond any textile norm and includes trials on animals that demonstrate the product’s safety and effectiveness even when consumed by fish and other animals. Furthermore, FUZE’s antimicrobial product filtered water in 99.7% of cases without the use of hazardous chemicals, offering more proof of its beneficial and non-destructive effects on the environment.
The Environmental Protection Agency (EPA) has approved FUZE, citing benefits for the product that have never been seen in the textile sector, in addition to FDA testing.
“We are significantly more approved than the industry average. According to Peterson, the EPA has confirmed the antimicrobial properties of FUZE’s applications in textiles and surfaces, demonstrating improved cooling and drying times, faster moisture wicking, and longer-lasting color protection.
Peterson went on, “FUZE has raised a much higher standard with its FDA testing, to fully understand what impact an anti-microbial product has on human interaction and long-term effect. While FUZE supports normal testing efforts used to identify the efficacy and environmental impact of all anti-microbial products, FUZE has raised a much higher standard.” FUZE is committed to a far higher level of accountability as we consider the future of our sector and how it will affect coming generations.
Fuze is a division of EVOQ, a scientific firm that develops cutting-edge technologies for the textile, materials, and life sciences sectors. Under both standard and stressed conditions, the company’s multi-patented high-volume laser production process produces a product with a consistent, exact shape and no ion emissions. These characteristics mark a substantial scientific breakthrough with the potential for a wide range of applications.
